Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9271812 | 0.79 | HPGDS (0.33) | — | |
| SCHEMBL6008799 | 0.69 | PTGS1 (0.39) | PTGS1PTGS2 | |
| SCHEMBL3618030 | 0.67 | PTGS1 (0.40) | PTGS1PTGS2 | |
| SCHEMBL9424431 | 0.61 | PTGS1 (0.39) | PTGS1PTGS2 | |
| SCHEMBL15470616 | 0.60 | PARP1 (0.39) | PTGS1PTGS2 | |
| SCHEMBL4263732 | 0.60 | — | — | |
| SCHEMBL9119829 | 0.58 | PTGS2 (0.54) | PTGS1PTGS2 | |
| SCHEMBL9119528 | 0.58 | PTGS1 (0.54) | PTGS1 | |
| SCHEMBL9122434 | 0.58 | PTGS2 (0.54) | PTGS1PTGS2 | |
| SCHEMBL9424672 | 0.58 | ADRA2A (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0652874-B1 | 2-HETEROCYCLIC-5-HYDROXY-1,3-PYRIMIDINES USEFUL AS ANTIINFLAMMATORY AGENTS | WARNER LAMBERT CO (US) | 2003-11-05 | — | — | EP | claimed |
| EP-0652874-A1 | 2-HETEROCYCLIC-5-HYDROXY-1,3-PYRIMIDINES USEFUL AS ANTIINFLAMMATORY AGENTS | WARNER-LAMBERT COMPANY (US) | 1995-05-17 | — | — | EP | claimed |
| US-5312821-A | Antiulcer agents | WARNER-LAMBERT COMPANY (US) | 1994-05-17 | — | — | US | claimed |
| WO-1994003448-A1 | 2-HETEROCYCLIC-5-HYDROXY-1,3-PYRIMIDINES USEFUL AS ANTIINFLAMMATORY AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-02-17 | — | — | WO | claimed |
| US-5240929-A | Lipoxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 1993-08-31 | — | — | US | claimed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| EP-0652874-B1 | 2-HETEROCYCLIC-5-HYDROXY-1,3-PYRIMIDINES USEFUL AS ANTIINFLAMMATORY AGENTS | WARNER LAMBERT CO (US) | 2003-11-05 | — | — | EP | disclosed |
| US-5312821-A | Antiulcer agents | WARNER-LAMBERT COMPANY (US) | 1994-05-17 | — | — | US | disclosed |
| US-5240929-A | Lipoxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 1993-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | PTGS1 76/4885PTGS2 99/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | PTGS1 76/4885PTGS2 99/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | PTGS1 593/4885PTGS2 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.